Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Molecular Templates stock | $8.94

Learn how to easily invest in Molecular Templates stock.

Molecular Templates, Inc is a biotechnology business based in the US. Molecular Templates shares (MTEM) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Templates employs 247 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Molecular Templates

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTEM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Molecular Templates stock price (NASDAQ: MTEM)

Use our graph to track the performance of MTEM stocks over time.

Molecular Templates shares at a glance

Information last updated 2021-07-28.
Latest market close$8.94
52-week range$6.41 - $15.19
50-day moving average $7.92
200-day moving average $9.82
Wall St. target price$15.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.79

Buy Molecular Templates shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Molecular Templates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Templates price performance over time

Historical closes compared with the close of $8.94 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 15.80%
3 months (2021-04-30) -4.49%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Molecular Templates financials

Revenue TTM $17.9 million
Gross profit TTM $-74,120,000
Return on assets TTM -31.83%
Return on equity TTM -114.17%
Profit margin 0%
Book value $1.93
Market capitalisation $409.5 million

TTM: trailing 12 months

Shorting Molecular Templates shares

There are currently 1.6 million Molecular Templates shares held short by investors – that's known as Molecular Templates's "short interest". This figure is 0.9% up from 1.6 million last month.

There are a few different ways that this level of interest in shorting Molecular Templates shares can be evaluated.

Molecular Templates's "short interest ratio" (SIR)

Molecular Templates's "short interest ratio" (SIR) is the quantity of Molecular Templates shares currently shorted divided by the average quantity of Molecular Templates shares traded daily (recently around 262793.15525876). Molecular Templates's SIR currently stands at 5.99. In other words for every 100,000 Molecular Templates shares traded daily on the market, roughly 5990 shares are currently held short.

However Molecular Templates's short interest can also be evaluated against the total number of Molecular Templates shares, or, against the total number of tradable Molecular Templates shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Molecular Templates's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Molecular Templates shares in existence, roughly 30 shares are currently held short) or 0.0396% of the tradable shares (for every 100,000 tradable Molecular Templates shares, roughly 40 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Molecular Templates.

Find out more about how you can short Molecular Templates stock.

Molecular Templates share dividends

We're not expecting Molecular Templates to pay a dividend over the next 12 months.

Have Molecular Templates's shares ever split?

Molecular Templates's shares were split on a 1:11 basis on 1 August 2017. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Molecular Templates shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Molecular Templates shares which in turn could have impacted Molecular Templates's share price.

Molecular Templates share price volatility

Over the last 12 months, Molecular Templates's shares have ranged in value from as little as $6.41 up to $15.19. A popular way to gauge a stock's volatility is its "beta".

MTEM.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Templates's is 1.2239. This would suggest that Molecular Templates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Molecular Templates overview

Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc.

Stocks similar to Molecular Templates

Frequently asked questions

What percentage of Molecular Templates is owned by insiders or institutions?
Currently 27.01% of Molecular Templates shares are held by insiders and 82.118% by institutions.
How many people work for Molecular Templates?
Latest data suggests 247 work at Molecular Templates.
When does the fiscal year end for Molecular Templates?
Molecular Templates's fiscal year ends in December.
Where is Molecular Templates based?
Molecular Templates's address is: 9301 Amberglen Boulevard, Austin, TX, United States, 78729
What is Molecular Templates's ISIN number?
Molecular Templates's international securities identification number is: US6085501095
What is Molecular Templates's CUSIP number?
Molecular Templates's Committee on Uniform Securities Identification Procedures number is: 608550109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site